Postdoctoral Fellowship at University of Jamestown, Germany.
Paula Abola is a highly qualified researcher with a strong academic background and significant contributions to Parkinson’s Disease research. Her expertise spans pharmaceutical management, clinical drug development, and medicinal chemistry, with extensive experience in clinical trials, regulatory affairs, and academia.
Publication Profile
Orcid
Education:
Paula Abola has a strong academic background in clinical research and pharmaceutical sciences. She is set to undertake a Postdoctoral Fellowship in Pharmaceutical Management at Sabi University, Canada, with a focus on Parkinson’s Disease (May 2027). She is currently pursuing a Doctor of Philosophy (PhD) in Clinical Research at the University of Jamestown, USA, emphasizing Parkinson’s Disease and shared decision-making in pharmacological management (May 2026). She completed her Master of Science in Clinical Drug Development at Queen Mary University of London, UK, in August 2023, with her dissertation exploring the efficacy of Monoamine Oxidase-B Inhibitor Rasagiline versus Liquid Levodopa-Carbidopa ND0612 Medication. She also holds a Bachelor of Science in Medicinal Chemistry & Chemical Biology from Jacobs University Bremen, Germany (June 2022).
Professional Experience:
Paula has held multiple academic and clinical roles. She currently serves as a Professor at Atlantic International University, USA (2025–Present), where she lectures in Chemical Biology. She also holds positions as an Adjunct Professor at Constructor University, Germany (2025–Present) and the University of Jamestown, USA (2024), mentoring students and lecturing on topics such as Causation and Correlation, Leadership, and Ethics.In the clinical sector, she worked as a Clinical Trial Regulatory Specialist at IQVIA, Germany (2024–2025), ensuring compliance in site activation and regulatory documentation. Previously, she served as a Remote Site Monitor and Clinical Trial Coordinator at Thermo Fisher Scientific, Germany (2022–2024), supporting regulatory submissions and monitoring clinical trials. Her early experience includes roles as an Analytical Chemist at Sirius Fine Chemicals SiChem GmbH, Germany (2019–2022) and Union Med PHOENIX Pharmacy Partnership, Latvia (2021–2022), specializing in high-performance liquid chromatography (HPLC) and mass spectrometry analyses.
Skills:
Paula has expertise in clinical research, pharmaceutical management, regulatory compliance, and trial coordination. She is skilled in data analysis, high-performance liquid chromatography (HPLC), gas chromatography (GC), nuclear magnetic resonance (NMR), and mass spectrometry. Additionally, she has strong mentoring, teaching, and academic research capabilities.
Awards & Recognitions:
Her academic excellence is reflected in her Summa Cum Laude distinction in her PhD program and Cum Laude in both her Master’s and Bachelor’s degrees. She has also been actively recognized in clinical research for her contributions to Parkinson’s Disease studies.
Research Focus:
Paula’s primary research interests center around Parkinson’s Disease, particularly in pharmacological management, shared decision-making, and movement disorders. Her recent work includes systematic reviews and meta-analyses on monoamine oxidase-B inhibitors, liquid subcutaneous Levodopa-Carbidopa, and adverse event incidences in Parkinson’s patients. She is also actively engaged in patient-practitioner knowledge studies and intra-individual voice variations in Parkinson’s Disease.
Top Noted Publication
Liquid Subcutaneous Levodopa-Carbidopa ND0612 Effects on Motor Symptoms in Individuals with Parkinson’s Disease: A Systematic Review and Meta-Analysis
-
Authors: Paula Abola, Mitchell Wolden, Kristin Lefebvre
-
Year: 2024
-
Journal: Advances in Parkinson’s Disease
Monoamine Oxidase-B Inhibitor Rasagiline Effects on Motor and Non-Motor Symptoms in Individuals with Parkinson’s Disease: A Systematic Review and Meta-Analysis
Conclusion
Paula Abola is an outstanding candidate for the Best Researcher Award, particularly in the fields of neuropharmacology, clinical trials, and Parkinson’s Disease management.
Her strong academic record, extensive publications, and leadership in movement disorder societies make her a compelling nominee. While her research is highly specialized, expanding into interdisciplinary innovation, AI applications, and broader pharmaceutical collaborations could further solidify her position as a top researcher.